Compare · ASPE vs NVS
ASPE vs NVS
Side-by-side comparison of Aspen Neuroscience Inc. (ASPE) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ASPE and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $310.17B, about 857.4x ASPE ($361.7M).
- ASPE has been more active in the news (10 items in the past 4 weeks vs 3 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 0 for ASPE).
- Company
- Aspen Neuroscience Inc.
- Novartis AG
- Price
- -
- -
- Market cap
- $361.7M
- $310.17B
- 1M return
- -
- +13.65%
- 1Y return
- -
- +27.85%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 10
- 3
- Recent ratings
- 0
- 25
Aspen Neuroscience Inc.
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases with high unmet medical need.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest ASPE
- SEC Form SCHEDULE 13D filed by Aspen Neuroscience Inc.
- SEC Form SCHEDULE 13G filed by Aspen Neuroscience Inc.
- SEC Form SCHEDULE 13G filed by Aspen Neuroscience Inc.
- Director Thompson Peter A. converted options into 2,589,132 shares and bought $15,000,000 worth of shares (1,000,000 units at $15.00) (SEC Form 4)
- Director Orbimed Advisors Llc converted options into 2,589,132 shares and bought $15,000,000 worth of shares (1,000,000 units at $15.00) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Aspen Neuroscience Inc.
- Large owner Arch Venture Fund X, L.P. bought $19,999,995 worth of shares (1,333,333 units at $15.00) and converted options into 2,421,589 shares (SEC Form 4)
- Large owner Arch Venture Partners Xiv, L.P. bought $18,000,000 worth of shares (1,200,000 units at $15.00) (SEC Form 4)
- Director Spaventa Andrew converted options into 250,415 shares (SEC Form 4)
- Executive Chair Hasnain Faheem converted options into 36,349 shares (SEC Form 4)
Latest NVS
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG